Medtech Public Comp Sheet and Valuation Guide

Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
 

Medtech’s underperformance leaves room for growth 

Public medtech companies failed to reach predicted milestones toward the end of 2024, particularly in life sciences where all but one major firm experienced share price declines greater than 7%. Exits were also muted in Q4, but our analysts expect an uptick in both exits and M&A activity in 2025 on the back of reduced antitrust activity and innovation in areas such as wearable medical devices. 

For key publicly traded companies, our Q4 2024 Medtech Public Comp Sheet and Valuation Guide tracks stock performance, changes in valuation, historical valuations, revenue growth, EBITDA growth, and EBITDA margins.